2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0563
    Ropivacaine 84057-95-4 99.98%
    Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is used for the research of neuropathic pain management.
    Ropivacaine
  • HY-D0846
    Diethyl pyrocarbonate 1609-47-8 ≥98.0%
    Diethyl pyrocarbonate is a potent, orally active, non-specific chemical inhibitor of RNase. Diethyl pyrocarbonate has been useful in vitro as an agent relatively specific for binding to imidazole of histidine. Diethyl pyrocarbonate inhibits central chemosensitivity in rabbits. Diethyl pyrocarbonate can modify Ser, Thr, His and Tyr residues. Diethyl pyrocarbonate can be used for modeling.
    Diethyl pyrocarbonate
  • HY-N0824
    Syringin 118-34-3 99.93%
    Syringin (Eleutheroside B) is an active natural phenolic glycoside possessing various pharmacological activities, including anti-inflammatory, anti-irradiation, anti-osteoporosis and anticancer activities. Syringin also can be used to enhance memory, relieve fatigue, improve human cognition and protect ischemia heart against cerebrovascular damage, etc.
    Syringin
  • HY-N2922
    β-Amyrin 559-70-6 99.95%
    β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound.
    β-Amyrin
  • HY-Y1282
    Sodium tetraborate decahydrate 1303-96-4 99.6%
    Sodium tetraborate decahydrate is an orally active biochemical reagent and antibacterial agent. Sodium tetraborate decahydrate leads to an increase in the activity of Catalase, Superoxide dismutase. Sodium tetraborate decahydrate reduces Hydrogen sulfide and the sulfate-reducing bacteria population of swine manure. Sodium tetraborate decahydrate serves as flame suppressant for wood cellulose. Sodium tetraborate decahydrate is a triglyceride transesterification catalyst. Sodium tetraborate decahydrate suppresses the formation of chlorinated by-products in Cl−-containing water. Sodium tetraborate decahydrate has a neuroprotective effect against chromium poisoning. Sodium tetraborate decahydrate can protect the heart from chromium damage at low doses. Sodium tetraborate in a low dose with an isolated application shows an antioxidant effect.
    Sodium tetraborate decahydrate
  • HY-101298
    Paprotrain 57046-73-8 99.85%
    Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.
    Paprotrain
  • HY-101348
    L-741626 81226-60-0 99.0%
    L-741626 is a selective D2 dopamine receptor antagonist, with the Ki values of 2.4, 100 and 220 nM for human D2, D3 and D4 receptors respectively.
    L-741626
  • HY-101418
    JNJ-47965567 1428327-31-4 99.79%
    JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pKis of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.
    JNJ-47965567
  • HY-103530
    CGP35348 123690-79-9 98.0%
    CGP 35348 is a selective, brain penetrant, centrally active GABAB receptor antagonist with an EC50 of 34 μM. CGP 35348 shows affinity for the GABAB receptor only. CGP 35348 has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage.
    CGP35348
  • HY-113301
    Hexacosanoic acid 506-46-7 98.15%
    Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
    Hexacosanoic acid
  • HY-113341
    7β-Hydroxycholesterol 566-27-8 99.72%
    7β-Hydroxycholesterol is an oxysterol that derived by the oxidation of cholesterol. 7β-hydroxycholesterol can induce cellular oxidative stress, apoptosis, and necrosis, resulting in cytotoxicity. 7β-hydroxycholesterol has antitumor activity.
    7β-Hydroxycholesterol
  • HY-124284
    Hexamethylene bisacetamide 3073-59-4 99.56%
    Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice.
    Hexamethylene bisacetamide
  • HY-150726
    ODN 1668 1186063-66-0 99.03%
    ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’.
    ODN 1668
  • HY-170621
    STAT1/3-IN-1 2958649-56-2 99.23%
    STAT1/3-IN-1 is a potent STAT1/3 inhibitor with potent anti-inflammatory effect. STAT1/3-IN-1 inhibits phosphorylation and nuclear translocation of STAT1/3 to modulate microglial inflammation, reduces LPS (HY-D1056)-induced pro-inflammatory cytokines (NO, IL-1β, IL-6, and TNF-α) and inflammatory mediators (iNOS, COX-2). STAT1/3-IN-1 exhibits low toxicity in mice. STAT1/3-IN-1 can be used for the research of neuroinflammation.
    STAT1/3-IN-1
  • HY-N0229S3
    L-Alanine-d4 18806-29-6 99.94%
    L-Alanine-d4 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-d4
  • HY-W010201
    Citronellol 106-22-9 98.40%
    Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis.
    Citronellol
  • HY-W018555
    D-Cysteine 921-01-7 ≥98.0%
    D-Cysteine, the D-isomer of cysteine, is an orally active antibacterial agent and a regulator of neural progenitor cell proliferation. D-Cysteine can inhibit Escherichia coli, Streptococcus mutans, and Streptococcus sanguinis. The no-observed-adverse-effect level of D-Cysteine in rats should be less than 500 mg/kg/day.
    D-Cysteine
  • HY-Y0319G
    Magnesium acetate tetrahydrate 16674-78-5 99.47%
    Magnesium acetate tetrahydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate regulates energy metabolism. Magnesium acetate tetrahydrate has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
    Magnesium acetate tetrahydrate
  • HY-W094516
    Disodium succinate hexahydrate 6106-21-4 99.5%
    Disodium succinate hexahydrate (Wormwood acid disodium hexahydrate) is an anti-anxiety agent with oral activity. Disodium succinate hexahydrate is an intermediate product of the tricarboxylic acid cycle. Disodium succinate hexahydrate is an important platform chemical. Disodium succinate hexahydrate can be used as surfactant, additive, ion chelating agent, flavoring agent and other applications in chemical, pharmaceutical and food fields.
    Disodium succinate hexahydrate
  • HY-W102714
    1,2-Cyclohexylenedinitrilotetraacetic acid 482-54-2 99.91%
    1,2-Cyclohexylenedinitrilotetraacetic acid (CDTA) is a chelating agent. 1,2-Cyclohexylenedinitrilotetraacetic acid has an ability to remove manganese from brain and liver (in vivo) and their sub-cellular fractions (in vitro), of rats pretreated with manganese sulphate.
    1,2-Cyclohexylenedinitrilotetraacetic acid
Cat. No. Product Name / Synonyms Application Reactivity